Home Featured Page 49

Featured

Latest

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran,...

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase...

“It Was Exactly What I Needed – Until I Was Arrested...

Rumination, the Default Mode Network, and How Neuroplasticity Changes Over Time

Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions,...

Why Psychedelic Practitioners Should be Trauma-Informed

BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

Microdosing at Work: How Psychedelics are Creating Better Leaders

Somatic Therapy and Psychedelics: How Body-Centered Approaches Are Revolutionizing Trauma Treatment

Psychedelics Today Live Podcast

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.